

DOI: <http://dx.doi.org/10.18203/2320-1770.ijrcog20181934>

Original Research Article

A comparative study between intramuscular oxytocin and intramuscular methyl ergometrine in the active management of third stage of labour

Devi Reddy Hema Swapnika*, Prema Priya G., S. Senthil Priya, A. S. Allirathinam

Department of Obstetrics and Gynecology, Vinayaka Mission Kirupananda Variyar Medical College and Hospital, Salem, Tamil Nadu, India

Received: 28 February 2018

Accepted: 28 March 2018

***Correspondence:**

Dr. Devi Reddy Hema Swapnika,
E-mail: hswapnika@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: To compare the efficacy of prophylactic IM oxytocin 10U and IM methyl ergometrine 0.2mg on duration of third stage of labour, amount of blood loss during the third stage of labour and associated side effects.

Methods: 50 low risk antenatal women with singleton pregnancy at term gestation in vertex presentation admitted for vaginal delivery, were randomly allocated into 2 groups of 25 each and managed actively in the third stage of labour either with 10 U oxytocin IM or with 0.2mg methyl ergometrine IM immediately after the birth of the baby. The main outcome measures were the difference between the 2 groups with regard to: duration of third stage of labour, blood loss by volume, difference in haemoglobin and haematocrit, need for blood transfusion, additional uterotonics and side effects of drugs.

Results: The mean duration of third stage of labour in the oxytocin group was 6.68 ± 2.17 min and in methergine group was 6.4 ± 1.93 min. Mean blood loss was 302 ± 75.6 ml and 282.8 ± 58.27 ml. Mean fall in Hb was 0.92 gm% and 0.812 gm%. Mean fall in PCV was 2.36% and 1.88%. 2 women in oxytocin group and 1 woman in methergine group received additional 0.2mg methergine. 3 women in both groups received 1 unit of blood transfusion. 8 women who received methergine had side effects while only one in the oxytocin group, with a p value 0.004 which is statistically significant.

Conclusions: This study has shown that both oxytocin and methyl ergometrine were equally efficacious. However, oxytocin had significantly better safety profile and lesser contraindications for usage.

Keywords: Active management of third stage of labour, Methyl ergometrine, Oxytocin, Post partum haemorrhage

INTRODUCTION

Pregnancy and child birth involve health risks for women even without any pre-existing health problems. Maternal mortality ratio (MMR) is used as a measure of the quality of health care system.

The third stage of labour is that period from delivery of the fetus to completed delivery of the placenta and its

attached membranes. Relatively little thought or teaching is devoted to the third stage of labour compared with that given to the first and second stages. "This indeed is the unforgiving stage of labour, and in it there lurks more unheralded treachery than in both the other stages combined. The normal case, within a minute, can become abnormal and successful delivery can turn swiftly to disaster" (Donald, 1979). This statement aptly describes the need for proper management of third stage of labour.

MMR in India is 174/100,000 live births (2011-2015) and 28% of maternal deaths are due to PPH.¹ PPH usually ranks in the top four causes of maternal mortality in developing countries along with hypertension, infection and unsafe abortions.² Anaemia is one of the most common cause of maternal morbidity and mortality in our country.

The best management of the third stage would be one that effectively minimizes serious problems such as blood loss and retained placenta, while interfering as little as possible with the physiological mechanisms of placental delivery and bonding between mother and baby and has few side effects. Recent studies show that there are still wide variations in practice around the world in the management of third stage of labour.

The present study was done to study the efficacy of 10 units of oxytocin given intramuscularly versus the use of methyl ergometrine 0.2mg intramuscularly in the active management of third stage of labour for the prevention of post partum haemorrhage.

METHODS

This was a prospective comparative study conducted in the department of Obstetrics and Gynaecology at VMKV Medical College and Hospital, Salem, during the period from January 2016 to June 2017. 50 low risk women with singleton pregnancy at term gestation with spontaneous onset of labour, admitted for vaginal delivery were eligible for the study.

Exclusion criteria

Grand multi, malpresentation, multiple pregnancy, gestational age <37 weeks and >41weeks, Hydramnios, intra uterine fetal demise, ante partum haemorrhage, previous history of post partum haemorrhage, instrumental delivery, caesarean section, fibroid complicating pregnancy, scarred uterus, medical disorders like severe anaemia (Hb <7g/dl), hypertension, cardiac disease, asthma, allergic disorders, blood dyscrasias.

Informed consent was obtained from women in early stage of labour who were eligible for the study. 50 women were randomised to 2 groups, 25 in each group, either to receive 10 U oxytocin IM or 0.2mg methyl ergometrine IM immediately after the birth of the baby. The third stage of labour was managed by clamping and cutting the cord immediately after the delivery of the baby, controlled cord traction and uterine massage. A flat bowl was kept under the buttocks of the women after the delivery of the placenta. Episiotomy wound repaired. Maternal pulse, BP was recorded immediately after delivery. One hour later the blood collected in the bowl was transferred to a measuring jar calibrated in ml and the amount of blood loss was noted.

Parameters studied

- Duration of third stage of labour
- Postpartum blood loss
- Hb% and PCV measured both before delivery at the time of admission and 24hours after delivery.
- Need for additional uterotonics
- Need for blood transfusion
- Side effects of uterotonics used
- Haemodynamically stable women were discharged from hospital after 24hours of delivery.

Statistical analysis

Data was entered in excel sheet and analysed using students paired t-test, student unpaired t-test and SPSS version 21. P value of <0.05 was regarded as statistically significant.

RESULTS

The total number of cases studied was 50. Age ranged from 19 -36 years. Out of the 50 subjects 34 (68%) were in the age group of 20-25 years, 10 (20%) were in age group 26-30years, 3 (6%) in <20 and >30 years (Table 1).

Table 1: Age distribution of women in oxytocin and methergine group.

Age	Frequency	Oxytocin	Methergine
<20	3	2	1
21-25	34	16	18
26-30	10	5	5
>30	3	2	1
Total	50	25	25

The mean duration of third stage of labour in the oxytocin group was 6.68±2.17min and in methergine group was 6.4±1.93 min. p value = 0.88 which is statistically insignificant (Table 2).

Table 2: Comparison of duration of third stage of labour in minutes.

Duration of 3 rd stage of labour in minutes	Mean	Sd	P
Oxytocin	6.68	2.174	0.88
Methergine	6.4	1.93	

Table 3: Comparison of blood loss in third stage of labour between the two groups.

Blood Loss in 3 rd stage of labour in ml	Mean	SD	P
Oxytocin	302	75.6	0.414
Methergine	282.8	58.27	

The mean blood loss in third stage of labour in the oxytocin group was 302±75.6 ml and in methergine

group was 282.8±58.27 ml. p value = 0.414 which is statistically insignificant (Table 3).

Table 4: Mean haemoglobin before and after delivery in both the groups.

Variable	Group	Mean	SD	P
Haemoglobin before delivery in g/dl	Oxytocin	10.16	0.806	0.666
	Methergine	10.25	0.745	
Haemoglobin after delivery in g/dl	Oxytocin	9.25	0.69	0.566
	Methergine	9.45	0.73	

The mean Hb% before delivery in the oxytocin group was 10.16± 0.806 and the mean Hb% in the methergine group was 10.25±0.745 with a p value 0.666 which is statistically insignificant. The mean Hb% 24hrs after delivery in the oxytocin group is 9.25±0.69 and in the methergine group is 9.45±0.73 with a p value 0.566 which is statistically insignificant (Table 4).

Table 5: Mean PCV before and after delivery in both the groups.

Variable	Group	Mean	SD	P
Before delivery	Oxytocin	29.908	1.737	0.120
	Methergine	30.12	2.147	
After delivery	Oxytocin	27.54	2.17	0.287
	Methergine	28.24	2.04	

The mean PCV in the oxytocin group was 29.908±1.737 and in the methergine group was 30.12±2.147 with a p value 0.120 which is statistically insignificant. The mean PCV 24hrs after delivery in the oxytocin group was 27.54±2.17 and in the methergine group was 28.24± 2.04 with a p value 0.287 which is statistically insignificant (Table 5).

Table 6: Difference in Hb and PCV before and after delivery.

Variable	Study group	Mean	SD	P value
Hb (g/dl)	Oxytocin	0.92	0.45	0.39
	Methergine	0.81	0.34	
PCV %	Oxytocin	2.36	1.424	0.12
	Methergine	1.88	1.051	

The mean fall in Hb in oxytocin group was 0.92gm% and in methergine group was 0.812gm%. The p value is 0.399 which is statistically insignificant. The mean fall in PCV in oxytocin group was 2.36% and in methergine group was 1.88%. p value = 0.12 which is statistically insignificant (Table 6).

Two women in oxytocin group received additional uterotonic of 0.2mg methergine and one woman who received methergine had received additional dose of 0.2mg methergine (Table 7).

Table 7: Need for additional uterotonics.

Additional uterotonics	No. of cases
Oxytocin	2
Methergine	1

Table 8: Side effects.

Side Effects	Oxytocin	Methergine	P
Vomiting	0	1	0.004
Nausea	1	5	
Headache	0	1	
Rise in blood pressure	0	1	
Fever	0	0	

A total of 8 women who received methergine had side effects, one had vomiting, one had headache, one had rise in blood pressure and 5 had nausea, while only one had nausea in the oxytocin group with a p value 0.004 which is statistically significant (Table 8).

Table 9: Need for blood transfusion.

Blood Transfusion	No. of cases
Oxytocin	3
Methergine	3

Blood transfusion was given to women with Hb <8.5g/dl (24hours after delivery) and 3 women in both the groups received 1unit of blood transfusion (Table 9).

DISCUSSION

The third stage of labour is defined as the “interval from the complete expulsion of the fetus to the complete expulsion of the placenta and membranes”. The average duration is about 15 minutes in both primigravidae and multiparae.³ This duration is reduced to 5minutes in active management.³

Two methods of management are currently in practice.⁴ Expectant and active management. Expectant management (traditional): In this, placental separation and its descent occur spontaneously or aided by gravity or nipple stimulation either manually or by breast feeding. Active management includes prophylactic administration of uterotonic agents, controlled cord traction and uterine massage

WHO recommends that sustained uterine massage is not needed in women who has received prophylactic oxytocin in prevention of PPH. However, uterine massage is strongly recommended in treatment of PPH.⁵ FIGO recommends that uterine massage after the delivery of placenta as the usual component of AMTSL.⁶ Active management of third stage of labour is superior to Expectant management in terms of blood loss, incidence of post partum haemorrhage, blood transfusions and other serious complications of third stage of labour.^{7,8}

Postpartum haemorrhage is the most common third stage complication and is the leading cause of maternal mortality. PPH affects 4-6% of all deliveries.⁹ Amount of blood loss in excess of 500ml following birth of the baby (WHO). The average blood loss following vaginal delivery, caesarean delivery and caesarean hysterectomy is 500ml, 1000ml, 1500ml respectively. Another proposed definition for PPH by ACOG is a 10% decline in haematocrit.¹⁰ Coombs has suggested a clinical definition of “need for blood transfusion”.¹¹

2/3rd of PPH occur in women with no identifiable risk factors without proper management PPH can rapidly progress to cause life threatening blood loss. Routine practice of active management of the third stage of labour has been shown to dramatically reduced haemorrhage by up to 60%. Giving uterotonic drug within one minute of birth is the component of active management of third stage of labour (AMTSL) that has greatest impact on the prevention of PPH. Every attendant at birth needs to have the knowledge, skills and critical judgement needed to carry out active management of third stage of labour.

In our study we evaluated the efficacy of the two drugs oxytocin and methyl ergometrine by recording the duration and blood loss in third stage, Hb percentage and PCV before and after 24 hours of delivery, side effects and need for additional uterotonics and need for blood transfusions.

Table 10: Mean duration of third stage of labour.

Duration of 3 rd stage of labour	Group	Mean	SD	P value
Present Study	Oxytocin	6.68	2.17	0.88
	Methergine	6.41	1.93	
Deepa R et al	Oxytocin	6.28	2.55	0.74
	Methergine	6.44	2.42	
Vandana S et al	Oxytocin	4.42	1.96	0.24
	Methergine	3.79	1.58	

In the present study, the mean duration of third stage of labour in the oxytocin group was 6.68min and in methergine group was 6.4 min. p value = 0.88 which is statistically insignificant. In the study conducted by Deepa R et al the mean duration of third stage of labour in the oxytocin group was 6.28min and in methergine group was 6.44min. The p value was 0.74 which is statistically insignificant.¹² In the study conducted by Vandana S et al the mean duration of third stage of labour in the oxytocin group was 4.42 min and in methergine group was 3.79 min. p value = 0.245 which is statistically insignificant (Table 10).¹³

In the present study, the mean blood loss in third stage of labour in the oxytocin group was 302 ml and in methergine group was 282.8 ml. p value = 0.414 which is statistically insignificant. In the study conducted by Deepa R et al the mean blood loss in third stage of labour

in the oxytocin group was 237 ml and in methergine group was 224 ml. p value = 0.319 which is statistically insignificant¹². In the study conducted by Vandana S et al the mean blood loss in third stage of labour in the oxytocin group was 166.64 ml and in methergine group was 156.72 ml. p value = 0.66 which is statistically insignificant (Table 11).¹³

Table 11: Distribution of blood loss (ml) in third stage of labour.

Blood loss	Group	Mean	SD	P value
Present Study	Oxytocin	302	75.61	0.414
	Methergine	282.8	58.27	
Deepa R et al	Oxytocin	237	69.58	0.319
	Methergine	224	50.75	
Vandana S et al	Oxytocin	166.64	64.17	0.666
	Methergine	156.72	82.98	

In the present study, the mean fall in Hb in oxytocin group was 0.92gm% and in methergine group was 0.812gm%. p value = 0.399 which is statistically insignificant. In the study conducted by Deepa R et al the mean fall in Hb in oxytocin group was 0.86gm% and in methergine group was 0.82gm%. p value = 0.21 which is statistically insignificant¹². In the study conducted by Shilu A et al the mean fall in Hb in oxytocin group was 1.10gm% and in methergine group was 1.20gm%. p value = 0.56 which is statistically insignificant (Table 12).¹⁴

Table 12: Assessment of mean fall in Hb gm%.

Hb	Group	Mean	SD	P value
Present Study	Oxytocin	0.92	0.45	0.39
	Methergine	0.81	0.34	
Deepa R et al	Oxytocin	0.86	0.07	0.21
	Methergine	0.82	0.29	
Shilu A et al	Oxytocin	1.10	0.80	0.56
	Methergine	1.20	1.00	

Table 13: Assessment of mean fall in PCV.

PCV	Group	Mean	SD	P
Present study	Oxytocin	2.36	1.424	0.12
	Methergine	1.88	1.051	
Deepa R et al	Oxytocin	0.91	0.64	0.2
	Methergine	0.93	0.65	
Shilu A et al	Oxytocin	3.8	3	0.99
	Methergine	3.8	3.4	

In the present study, the mean fall in PCV in oxytocin group was 2.36% and in methergine group was 1.88%. p value = 0.12 which is statistically insignificant. In the study conducted by Deepa R et al the mean fall in PCV in oxytocin group was 0.91% and in methergine group was 0.93%. p value = 0.2 which is statistically insignificant¹².

In the study conducted by Shilu Adhikari et al the mean fall in PCV in oxytocin group was 3.8% and in methergine group was 3.8%. p value = 0.99 which is statistically insignificant (Table 13).¹⁴

Table 14: Comparison of efficacy of other parameters.

	Variable	Oxytocin	Methergine
Present study	Additional uterotonics	2	1
	Blood transfusion	3	3
Deepa R et al	Additional uterotonics	6	0
	Blood transfusion	0	0
Adhikari S et al	Additional uterotonics	5	4
	Blood transfusion	2	1

In present study a total of two women in oxytocin group received additional uterotonic of 0.2 mg methergine and one woman who received methergine had received additional dose of 0.2mg methergine. Blood transfusion was given to 3 women in both the groups. In the study conducted by Deepa R et al 6 women of the oxytocin group required the use of additional uterotonics in the form of IM methergine and none of the women of either groups required blood transfusion.¹² In the study conducted by Shilu Adhikari et al the incidence of use of additional uterotonics was almost the same (Table 14).¹⁴

Table 15: Comparison of side effects.

	Variable	Oxytocin	Methergine
Present study	Vomiting	0	1
	Nausea	1	5
	Headache	0	1
	Rise in blood pressure	0	1
	Fever	0	0
Adhikari S et al	Variable	Oxytocin	Methergine
	Vomiting	1	1
	Nausea	0	2
	Headache	2	4
	Rise in blood pressure	2	2
Deepa R et al	Variable	Oxytocin	Methergine
	Vomiting	0	8
	Nausea	0	0
	Headache	0	0
	Rise in blood pressure	0	9
	Fever	0	0

In present study a total of 8 women who received methergine had significant side effects, one had vomiting,

one had headache, one had rise in blood pressure and 5 had nausea, while only one had nausea in the oxytocin group. In the study conducted by Shilu Adhikari et al the side effects of the uterotonics did not cause any serious adverse events. All the adverse effects were mild and they subsided spontaneously and none of the women required any medications for these effects¹⁴. In the study conducted by Deepa R et al 8 women who received methergine had vomiting and 9 had rise in blood pressure. While those who were given oxytocin alone did not have any significant side effect (Table 15).¹²

CONCLUSION

The usage of oxytocin in the active management of third stage of labour is beneficial in reducing the blood loss and thus helps in preventing post partum haemorrhage. Oxytocin is very safe to use with least side effects and can be used even in high risk women, it can be used even in hypertensive women and in those with cardiovascular disease.

In this study comparing IM oxytocin 10units and IM methylergometrine 0.2mg given in the third stage of labour, it was found that both methylergometrine and oxytocin were equally efficacious in reducing blood loss in the third stage of labour and effective in reducing the duration of third stage of labour.

However, in the view of occurrence of side effects and its limitations of methylergometrine, it can be concluded that oxytocin is more preferable than methylergometrine in the active management of third stage of labour.

ACKNOWLEDGMENTS

Authors would like to thank Dr.Navin Puttum Assistant Professor of Emergency Medicine, Vinayaka Missions University, for Statistical Analysis and helped in manuscript preparation.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. India Maternal mortality rate – Demographics [Internet]. [cited July 9, 2017]. Available at https://www.indexmundi.com/india/maternal_mortality_rate.html
2. The World Health Report 2005 - make every mother and child count [Internet]. [cited 2014 Sep 3]. Available at <http://www.who.int/whr/2005/en/>
3. Dutta DC. Textbook of Obstetrics. 7th Edition, New Central Book Agency Pvt. Ltd;2011:117-42.
4. Arulkumaran S, Arjun G, Penna LK. The management of labour. 3rd Ed. Hyderabad:

- universities press (India) private Ltd;2011;18:289-295.
5. World Health Organization. WHO Issue recommendations for postpartum haemorrhage. Geneva-2012 [internet] [cited 2014 Sep 1] Available at www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/
 6. FIGO Guidelines on the prevention and treatment of postpartum haemorrhage in Low-Resource settings [Internet]. [cited 2014 Sep 2]. Available at http://www.fogsi.org/index.php?option=com_content&view=article&id=351%3Afigo-guidelines-on-the-prevention-and-treatment-of-postpartum-haemorrhage-in-low-resource-settings&catid=39%3Amiscellanea%26Itemid=238.
 7. The Cochrane Collaboration, editor. Cochrane Database of Systemic Reviews: reviews [Internet]. Chichester, UK:John Wiley and Sons, Ltd; 1996 [cited 2014 sep 3]. Available at http://apps.who.int/rhUguidelines/appraisal_pph/en/index.html
 8. Active versus expectant management for women in the third stage of labour. [inteme] [cited 2014 sep 14] Available at http://apps.who.int/rhl/pregnancy_childbirth/3rd_stage/cd007412_abalose_com/en/
 9. Foley MR, Strong TH, Garite TJ. McGraw Hill Professional, 2004. *Obstetric Intensive Care Manual* 2nd edition. 2004; 24-7
 10. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. *Obstet Gynecol.* 2006 Oct;108(4):1039-47.
 11. Combs CA. Factors associated with postpartum haemorrhage with vaginal birth. *Obstet Gynecol* 1991;77:69-76.
 12. Rajendran D, Mamatha S, Siddesh A, Gowda S. Oxytocin versus methyl ergometrine in the management of third stage of labor: a comparative study from a South Indian tertiary care hospital. *Int J Reprod Contracept Obstet Gynecol.* 2016;5:1327-30.
 13. Vandana Satwe, Jyoti Salunkhe, Seema Satwe, Sheetal Samson. Injection Oxytocin versus Injection Methergine in Active Management of Third Stage of Labour. *IJSR.* 2014;3(3):353-8.
 14. Adhikari S, Rana A, Bista KD. Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. *Nepal J Obstet Gynaecol.* 2007;2(2):24-8.

Cite this article as: Swapnika DRH, Priya GP, Priya SS, Allirathinam AS. A comparative study between intramuscular oxytocin and intramuscular methyl ergometrine in the active management of third stage of labour. *Int J Reprod Contracept Obstet Gynecol* 2018;7:1943-8.